

Technology Appraisal Committee Meeting (Committee D)

Minutes: Unconfirmed

Date and Time: 31 May 2017, 10.00 - 16.30

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Professor Gary McVeigh (Chair) 2. Dr Lindsay Smith (Vice Chair) 3. Dr Matthew Bradley 4. Dr Ian Davidson 5. Mrs Susan Dutton 6. Professor Rachel Elliott 7. Mrs Gillian Ells 8. Professor Paula Ghaneh 9. Dr Peter Hall 10. Dr Rebecca Harmston 11. Sumithra Maheswaran 12. Dr David Meads 13. Dr Malcolm Oswald 14. Professor Oluwafemi Oyebode 15. Mr William Turner	Present for all notes Present for all notes
-----------------	---	---

In attendance:

Dr Xavier Armoiry	Evidence Review Group representative, Warwick Evidence	Present for notes 1 to 11
Dr Nigel Armstrong	Evidence Review Group representative, Kleijnen Systematic Reviews	Present for notes 15 to 23
Dr Peter Auguste	Evidence Review Group representative, Warwick Evidence	Present for notes 1 to 11
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Professor Peter Clark	CDF Clinical Lead, NHS England	Present for notes 1 to 11

Melanie Costin	Patient Expert, nominated by Fight Bladder Cancer	Present for notes 1 to 11
Christian Griffiths	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 14
Dr Rhona McMenemin	Consultant Clinical Oncologist, Clinical Expert, nominated by NCRI-ACP-RCP-RCR- BUG	Present for notes 1 to 11
Dr Hema Mistry	Evidence Review Group representative, Warwick Evidence	Present for notes 1 to 11
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Alex Sexton	Administrator, National Institute for Health and Care Excellence	Present for all notes
Thomas Strong	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 14
Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for notes 15 to 26
Helen Tucker	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 15 to 26
Nwamaka Umeweni	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 15 to 26
Andrew Winterbottom	Patient Expert, nominated by Fight Bladder Cancer	Present for notes 1 to 11

Non-public observers:

Steve Estevao	Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 26
Michele Hilton-Boon	Research Fellow, National Institute for Health and Care Excellence	Present for notes 1 to 26
Hayley Sharp	Senior Editor, National Institute for Health and Care Excellence	Present for notes 1 to 26
Lydia Shears	Public Involvement Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 11
Kate Weir	Editor, National Institute for Health and Care Excellence	Present for notes 1 to 26

Notes**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Pembrolizumab for treating urothelial cancer after platinum-based chemotherapy and Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy
2. Apologies were received from Dr Aomesh Bhatt, Professor David Bowen, Professor Simon Dixon and Dr Paula Parvulescu.

Any other Business

3. None

Appraisal of pembrolizumab for treating urothelial cancer after platinum-based chemotherapy

Note: at the date of this meeting the Committee for Medicinal Products for Human Use (at European Medicines Agency) had not yet given its regulatory opinion for pembrolizumab for treating urothelial cancer after platinum-based chemotherapy and as a consequence this discussion took place in a Part 2 session (closed to public observers). In line with the 3.1.22 of the [guide to the processes of technology appraisal](#) NICE will not make public, or circulate among consultees and commentators any

documents for consultation or guidance on a technology until UK regulatory approval has been granted and the technology's price is known.

Part 2 – Closed session

4. The Chair welcomed the invited experts Dr Xavier Armoiry, Dr Peter Auguste, Professor Peter Clark, Melanie Costin, Dr Rhona McMenemin, Dr Hema Mistry, and Andrew Winterbottom to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals Ltd to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
 - 6.1. Dr Matthew Bradley, Dr Ian Davidson, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Peter Hall, Dr Rebecca Harmston, Professor Gary McVeigh, Sumithra Maheswaran, Dr David Meads, Dr Malcolm Oswald, Professor Oluwafemi Oyebode and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating urothelial cancer after platinum-based chemotherapy.
 - 6.2. William Turner declared a non-specific personal financial interest as his wife holds shares in Worldwide Healthcare Trust PLC.
 - 6.2.1. It was agreed that this declaration would prevent William Turner from participating in this section of the meeting.
7. The Chair asked all NICE Staff to declare any relevant interests.
 - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating urothelial cancer after platinum-based chemotherapy.
8. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 8.1. Dr Xavier Armoiry, Dr Peter Auguste, Professor Peter Clark, Melanie Costin, Dr Rhona McMenemin, Dr Hema Mistry, and Andrew Winterbottom declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating urothelial cancer after platinum-based chemotherapy.
9. The Chair introduced the lead team, Professor Rachel Elliott, Dr Malcolm Oswald and William Turner, who gave presentations on the clinical effectiveness and cost

effectiveness of pembrolizumab for treating urothelial cancer after platinum-based chemotherapy.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
11. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
12. Discussion on confidential information continued. This information was supplied by the company.
13. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating urothelial cancer after platinum-based chemotherapy.
14. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy

Part 1 – Open session

15. The Chair welcomed the invited experts, Dr Nigel Armstrong and Professor Peter Clark, to the meeting and they introduced themselves to the Committee.
16. The Chair welcomed company representatives from Takeda UK to the meeting.
17. The Chair asked all Committee members to declare any relevant interests
 - 17.1. Dr Matthew Bradley, Dr Ian Davidson, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Dr Peter Hall, Dr Rebecca Harmston, Professor Gary McVeigh, Sumithra Maheswaran, Dr David Meads, Dr Malcolm Oswald, Professor Oluwafemi Oyebode and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy
 - 17.2. William Turner declared a non-specific personal financial interest as his wife holds shares in Worldwide Healthcare Trust PLC.
 - 17.2.1. It was agreed that this declaration would prevent William Turner from participating in this section of the meeting.
18. The Chair asked all NICE Staff to declare any relevant interests.
 - 18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the

technologies to be considered as part of the appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.

19. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 19.1. They declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.
20. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
22. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
23. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. Discussion on confidential information continued. This information was supplied by the company.
25. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy.
 - 25.1. The committee decision was based on consensus.
26. The Committee instructed the technical team to prepare the [Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD)] in line with their decisions.

Date, time and venue of the next meeting

27. Wednesday 28 June 2017, 10.00 – 17.00, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.